Prof Mason speaks about the results of an inter-group trial conducted by the UK Medical Research Council in collaboration with the National Cancer Institute of Canada. This trial looked at men with locally advanced or localised non-metastatic prostate cancer and challenging the results of a previous study that treatment should be a combination of radiotherapy and hormone therapy. Interim analysis of the results has shown an increase in prostate cancer specific mortality and overall survival when both hormone therapy and radiotherapy were used. Prof Mason discusses two other trials that he is running: one is a study comparing the long term use of hormone therapy with either androgen therapy alone or with an androgen therapy combination; the second study is looking at the role and timing of salvage radiotherapy.